GlassScriptPhysician profile
Robert S Flynn
NPI 1982812681
$8,527.63
in general payments reported to CMS, 2019-2025
29 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $228 · 2021: $846 · 2022: $1,293 · 2023: $1,936 · 2024: $2,099 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,327 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,327.22 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,583.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,015.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.46 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $508.54 | 2022-2025 | |
| Janssen Biotech, INC. | $461.97 | 2019-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $229.84 | 2019-2023 | Sucraid |
| Pfizer INC. | $220.60 | 2019-2025 | |
| Ardelyx, INC. | $206.51 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $166.80 | 2019-2025 | |
| Medtronic, INC. | $129.78 | 2024 | Endoflip, Pillcam |
| Merck Sharp & Dohme LLC | $118.58 | 2019-2023 | Dificid |
| Celgene Corporation | $117.15 | 2021-2023 | |
| Braintree Laboratories, INC. | $98.11 | 2019-2025 | Suflave, Sutab |
| Lilly USA, LLC | $89.17 | 2023-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $85.43 | 2020-2025 | Linzess |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $74.16 | 2021-2023 | Rebyota |
| Celltrion USA INC. | $73.63 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $63.04 | 2024-2025 | Voquezna |
| Sandoz INC. | $61.55 | 2023-2025 | Hyrimoz |
| Organon LLC | $61.49 | 2024-2025 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $58.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Pharmacosmos Therapeutics INC. | $48.93 | 2021 | |
| Ucb, INC. | $47.21 | 2019 | |
| Nestle Healthcare Nutrition INC. | $46.86 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $24.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.45 | 2024 | Bylvay |
| Phadia US INC. | $18.75 | 2022 | |
| Intercept Pharmaceuticals, INC. | $17.16 | 2023 | Ocaliva |
| Allergan, INC. | $15.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Flynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.